Clinical trial · Interventional
Safety and Efficacy of Oncoxin in Hepatocellular Carcinoma (HCC)
Study to Evaluate Safety and Therapeutic Efficacy of a Nutritional Supplement 'Oncoxin' in Patients With Hepatocellular Carcinoma
NCT01392131CI-TRIAL-00008655unknownPhase 1 / Phase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Oncoxin is safe and results in improved survival in patients with hepatocellular carcinoma
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Oncoxin | Dietary Supplement | — | UNRESOLVED |
| Supportive treatment | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Oncoxin will be administered orally
- description
- 20 patients will receive syrup Oncoxin 25 ml bd and capsule Oncoxin 1 cap bd for 24 weeks
- interventionNames
- Dietary Supplement: Oncoxin
- type
- ACTIVE_COMPARATOR
- label
- Supportive treatment
- description
- 20 patients with hepatocellular carcinoma will receive supportive treatment only
- interventionNames
- Other: Supportive treatment
Primary outcomes (1)
- measure
- Number of patients who have prolonged survival after receiving Oncoxin
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Patients with HCC irrespective of etiology, age, gender and status of underlying liver disease. * Patients with HCC who are not suitable candidates for established modalities of treatment i.e. surgery and/or chemotherapy. * Patients with HCC who have evidence of tumor metastasis * Patients with HCC who are voluntarily unwilling to take established modalities of treatment i.e. surgery and/or chemotherapy. * Patients with HCC in whom all possible treatment options have been exhausted. Exclusion Criteria: * Patients with HCC who are suitable candidates for established modalities of treatment i.e. surgery and/or chemotherapy. * Patients with HCC who have no evidence of tumor metastasis * Patients with HCC who are willing to take established modalities of treatment i.e. surgery and/or chemotherapy. * Patients with HCC who are voluntarily unwilling to be included in the trial
References
Publications (0)
Data not yet available
No reference posted for this study.